Enanta Pharmaceuticals Stock (NASDAQ:ENTA)
Previous Close
$14.14
52W Range
$4.09 - $15.34
50D Avg
$12.00
200D Avg
$8.24
Market Cap
$314.67M
Avg Vol (3M)
$749.42K
Beta
0.97
Div Yield
-
ENTA Company Profile
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
ENTA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| FHTX | Foghorn Therapeutics Inc. |
| PYXS | Pyxis Oncology, Inc. |
| TNYA | Tenaya Therapeutics, Inc. |
| AVIR | Atea Pharmaceuticals, Inc. |
| PRLD | Prelude Therapeutics Incorporated |
| ASMB | Assembly Biosciences, Inc. |
| NAUT | Nautilus Biotechnology, Inc. |
| VYGR | Voyager Therapeutics, Inc. |
| CRBU | Caribou Biosciences, Inc. |
| IMRX | Immuneering Corporation |